<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Reumatologia</journal-id><journal-id journal-id-type="iso-abbrev">Reumatologia</journal-id><journal-id journal-id-type="publisher-id">RU</journal-id><journal-title-group><journal-title>Reumatologia</journal-title></journal-title-group><issn pub-type="ppub">0034-6233</issn><issn pub-type="epub">2084-9834</issn><publisher><publisher-name>Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6263305</article-id><article-id pub-id-type="publisher-id">79502</article-id><article-id pub-id-type="doi">10.5114/reum.2018.79502</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Paper</subject></subj-group></article-categories><title-group><article-title>Differential diagnosis of idiopathic inflammatory myopathies in adults &#x02013; the first step when approaching a patient with muscle weakness</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Szcz&#x00119;sny</surname><given-names>Piotr</given-names></name></contrib><contrib contrib-type="author"><name><surname>&#x0015a;wierkocka</surname><given-names>Katarzyna</given-names></name></contrib><contrib contrib-type="author"><name><surname>Olesi&#x00144;ska</surname><given-names>Marzena</given-names></name></contrib></contrib-group><aff>Department of Systemic Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology, and Rehabilitation, Warsaw, Poland</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Piotr Szcz&#x00119;sny, Department of Systemic Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology, and Rehabilitation, 1 Sparta&#x00144;ska St., 02-637 Warsaw, Poland. e-mail: <email xlink:href="piotr_szczesny@live.com">piotr_szczesny@live.com</email></corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>10</month><year>2018</year></pub-date><pub-date pub-type="ppub"><year>2018</year></pub-date><volume>56</volume><issue>5</issue><fpage>307</fpage><lpage>315</lpage><history><date date-type="received"><day>25</day><month>6</month><year>2018</year></date><date date-type="accepted"><day>25</day><month>9</month><year>2018</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2018 Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.</license-p></license></permissions><abstract><p>Despite its misleading adjective, the most commonly used diagnostic criteria of idiopathic inflammatory myopathies (IIM) are applicable only after all other non-autoimmune muscle diseases have been excluded. It makes differential diagnosis the first step when approaching a patient with muscle weakness. This article is designed to list the most common conditions from which to differentiate in rheumatological care. In fact, many patients with the diseases described here have been initially misdiagnosed with IIM. For the purpose of this article, only the most commonly found and important conditions according to the authors are listed with the essence of information; other autoimmune muscle diseases, such as sarcoidosis and eosinophilic myositis, are not portrayed. The attached bibliography may serve as a source, when further exploration of a specific subject is needed.</p></abstract><kwd-group><kwd>myositis</kwd><kwd>differential diagnosis</kwd><kwd>myopathies in adults</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Idiopathic inflammatory myopathies (IIM) are rare conditions with incidence ranging from 5.5 to 7.7 cases per million in developed countries. The list comprises polymyositis, dermatomyositis (including juvenile, amyopathic, and sine-dermatitis form), inclusion body myositis, immune-mediated necrotising myopathy (IMNM), and focal autoimmune myositis. In all of these conditions, due to abnormal reaction of the immune system, striated muscles become gradually inflamed with various intensities and irregular patterns. This reduces the number of rhabdomyocytes responding to each signal given by motor units to contract and consequently produces vast, rather symmetric muscle weakness of abrupt or subacute onset. Muscle weakness, however, is not synonymous with fatigue, although the latter occurs as a frequent accompanying sign of many autoimmune diseases, thus the physical examination should be targeted at differentiating these two. Fatigability of the muscles is not a core feature of inflammatory myopathies, either.</p><p>The essence of treatment for each type of IIM is immunosuppression, often with the use of glucocorticosteroids. Because this therapy itself is the cause of morbidity, it must be administered carefully. Knowing that delaying the treatment may cause irreversible damage, many doctors decide not to wait until all possible grounds of myopathy are excluded. However, as described below, in some cases administration of glucocorticosteroids may result in serious aggravation of symptoms.</p></sec><sec id="sec2"><title>Toxic myopathies</title><p>Many substances may be harmful to striated muscle fibres [<xref rid="cit0001" ref-type="bibr">1</xref>], among which the flagship examples are 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) inhibitors &#x02013; statins. Usage of these drugs is more and more common in developed countries, and their efficacy in reducing mortality and disability from cardiovascular and cerebrovascular diseases is unquestionable; however, 5&#x02013;20% of patients complain of musculoskeletal symptoms that cause withdrawal of the therapy; 0.4&#x02013;0.9 per 10,000 person-years experience rhabdomyolysis [<xref rid="cit0002" ref-type="bibr">2</xref>], which can be fatal, if untreated.</p><p>The possible pathomechanism might be associated with overexpression of MHC-I in the rhabdomyocytes [<xref rid="cit0003" ref-type="bibr">3</xref>] and up-regulation of HMGCR [<xref rid="cit0004" ref-type="bibr">4</xref>]. Patients usually complain of proximal muscle weakness of the lower extremities and less commonly myalgia, which begins two weeks to four years after the initiation of the drug. Lipophilic statins, such as atorvastatin and simvastatin, are more likely to cause the myopathy than are hydrophilic agents. Laboratory tests may show significant elevation of creatine kinase (CK), proportional to the muscle damage, and myoglobinuria and renal damage can also occur. Electromyography shows typical myopathic units, and the histopathological picture presents with muscle fibre necrosis with prominent phagocytosis and small basophilic regenerating fibres; infiltration of inflammatory cells is scarce &#x02013; in some instances only perivascular inflammation is present [<xref rid="cit0005" ref-type="bibr">5</xref>].</p><p>In most cases it is sufficient just to reduce the dose of the drug or switch to another substance; CK elevation usually normalises after 2&#x02013;3 months but can persist for as long as 14 months. What is remarkable is that some patients develop anti-HMG-CoA antibodies and a chronic condition known as statin-induced immune-mediated necrotising myopathy (IMNM, formerly: necrotising autoimmune myopathy) [<xref rid="cit0006" ref-type="bibr">6</xref>], which requires immunosuppressive treatment, so follow-up in these patients is necessary [<xref rid="cit0007" ref-type="bibr">7</xref>]. The risk factors of statin-induced myopathy are presented in <xref rid="t0001" ref-type="table">Table I</xref>.</p><table-wrap id="t0001" position="float"><label>Table I</label><caption><p>Risk factors of statin-induced myopathy [<xref rid="cit0001" ref-type="bibr">1</xref>, <xref rid="cit0002" ref-type="bibr">2</xref>]</p></caption><table frame="border" rules="rows" width="100%"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Risk factors of statin-induced myopathy</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1. Concomitant medications that interact with CYP3A4 and increase serum statin concentration (e.g. antibiotics, antifungals, calcium channel blockers, antiretrovirals, antidepressants)</td></tr><tr><td align="left" rowspan="1" colspan="1">2. Single nucleotide polymorphism (SNP) rs4363657 in the <italic>SLCO1B1</italic> gene on chromosome 12. Patients homozygous for this SNP have above 15% of risk of developing myopathy within the first year of therapy</td></tr><tr><td align="left" rowspan="1" colspan="1">3. Female gender</td></tr><tr><td align="left" rowspan="1" colspan="1">4. Alcoholism</td></tr><tr><td align="left" rowspan="1" colspan="1">5. Hypothyroidism</td></tr><tr><td align="left" rowspan="1" colspan="1">6. Renal dysfunction</td></tr><tr><td align="left" rowspan="1" colspan="1">7. Liver dysfunction</td></tr><tr><td align="left" rowspan="1" colspan="1">8. Low BMI</td></tr><tr><td align="left" rowspan="1" colspan="1">9. Prior personal history of statin intolerance</td></tr><tr><td align="left" rowspan="1" colspan="1">10. Family history of statin intolerance</td></tr></tbody></table></table-wrap><p>Other drugs can also cause myopathy of varying severity, as presented in <xref rid="t0002" ref-type="table">Table II</xref>. What is typical for this group is that the symptoms and CK levels usually normalise days-weeks after cessation of the drug.</p><table-wrap id="t0002" position="float"><label>Table II</label><caption><p>ATC division of myopathy-causing substances [<xref rid="cit0001" ref-type="bibr">1</xref>, <xref rid="cit0007" ref-type="bibr">7</xref>&#x02013;<xref rid="cit0009" ref-type="bibr">9</xref>]</p></caption><table frame="border" rules="rows" width="100%"><tbody><tr><td align="left" rowspan="1" colspan="1">A 02 &#x02013; Drugs for acid related disorders</td><td align="left" rowspan="1" colspan="1">omeprazole, cimetidine</td></tr><tr><td align="left" rowspan="1" colspan="1">C 01 &#x02013; Cardiac therapy</td><td align="left" rowspan="1" colspan="1">amiodarone, procainamide</td></tr><tr><td align="left" rowspan="1" colspan="1">C 07 &#x02013; Beta blocking agents</td><td align="left" rowspan="1" colspan="1">labetalol</td></tr><tr><td align="left" rowspan="1" colspan="1">C 10 &#x02013; Lipid modifying agents</td><td align="left" rowspan="1" colspan="1">statins: simvastatin &#x0003e; lovastatin &#x0003e; atorvastatin &#x0003e; rosuvastatin &#x0003e; pravastatin &#x0003e; fluvastatin<break/>other: gemfibrozil, niacin, ezetimibe, colevesam, fenofibrate</td></tr><tr><td align="left" rowspan="1" colspan="1">D 07 &#x02013; Corticosteroids, dermatological preparations</td><td align="left" rowspan="1" colspan="1">group: glucocorticosteroids (dexamethasone &#x0003e; betamethasone &#x0003e; triamcinolone)</td></tr><tr><td align="left" rowspan="1" colspan="1">D 10 &#x02013; Anti-acne preparations</td><td align="left" rowspan="1" colspan="1">isoretinion</td></tr><tr><td align="left" rowspan="1" colspan="1">G 04 &#x02013; Urologicals</td><td align="left" rowspan="1" colspan="1">finasteride</td></tr><tr><td align="left" rowspan="1" colspan="1">J 05 &#x02013; Antivirals for systemic use</td><td align="left" rowspan="1" colspan="1">zidovudine, lamivudine</td></tr><tr><td align="left" rowspan="1" colspan="1">L 01 &#x02013; Antineoplastic agents</td><td align="left" rowspan="1" colspan="1">vincristine, imatinib, gemcitabine, ipilimumab</td></tr><tr><td align="left" rowspan="1" colspan="1">L 03 &#x02013; Immunostimulants</td><td align="left" rowspan="1" colspan="1">interferon</td></tr><tr><td align="left" rowspan="1" colspan="1">L 04 &#x02013; Immunosuppressants</td><td align="left" rowspan="1" colspan="1">cyclosporine, tacrolimus, group: tumour necrosis-factors</td></tr><tr><td align="left" rowspan="1" colspan="1">M 01 &#x02013; Anti-inflammatory and antirheumatic products</td><td align="left" rowspan="1" colspan="1">D-penicillamine</td></tr><tr><td align="left" rowspan="1" colspan="1">M 04 &#x02013; Antigout preparations</td><td align="left" rowspan="1" colspan="1">colchicine</td></tr><tr><td align="left" rowspan="1" colspan="1">N 01 &#x02013; Anaesthetics</td><td align="left" rowspan="1" colspan="1">propofol, cocaine</td></tr><tr><td align="left" rowspan="1" colspan="1">N 02 &#x02013; Analgesics</td><td align="left" rowspan="1" colspan="1">pethidine, pentazocine, pritramide</td></tr><tr><td align="left" rowspan="1" colspan="1">N 03 &#x02013; Antiepileptics</td><td align="left" rowspan="1" colspan="1">lamotrigine, phenytoin</td></tr><tr><td align="left" rowspan="1" colspan="1">N 06 &#x02013; Psychoanaleptics</td><td align="left" rowspan="1" colspan="1">L-tryptophan (eosinophilia myalgia, toxic oil syndrome syndrome), amphetamine</td></tr><tr><td align="left" rowspan="1" colspan="1">N 07 &#x02013; Other nervous system drugs</td><td align="left" rowspan="1" colspan="1">heroin</td></tr><tr><td align="left" rowspan="1" colspan="1">P 01 &#x02013; Antiprotozoals</td><td align="left" rowspan="1" colspan="1">hydroxychloroquine, chloroquine</td></tr><tr><td align="left" rowspan="1" colspan="1">Toxicology</td><td align="left" rowspan="1" colspan="1">South American rattlesnake (Crotalus durissus), inhalative toluene</td></tr></tbody></table></table-wrap><p>Toxic myopathies include many that are caused by chronic alcohol abuse. Ethanol usually causes peripheral and central neuropathy, but it can also lead to acute necrotising or hypokalaemic myopathy, chronic alcoholic myopathy, asymptomatic alcoholic myopathy, and alcoholic cardiomyopathy. Acute necrotising myopathy occurs after intensive exposure to the substance, presents with muscle weakness, cramping, myalgia, and elevated CK levels, and can lead to acute renal failure. It presents with irritable myopathy on EMG, and muscle biopsy reveals widespread fibre necrosis. The condition resolves within weeks of abstinence. Acute hypokalaemic myopathy with potassium levels &#x0003c; 2 mmol/l, elevated CK levels, and vacuolisation of muscle fibres in muscle biopsy is treated with careful potassium supplementation [<xref rid="cit0008" ref-type="bibr">8</xref>].</p></sec><sec id="sec3"><title>Endocrinological causes of myopathy</title><p>Steroid myopathy (caused by pituitary or adrenal gland hypersecretion, or iatrogenic) has to be considered in differential diagnosis at the beginning but also in the course of treatment as part of the spectrum of the patient&#x02019;s symptoms. This condition concerns about 50&#x02013;80% of patients with endogenous Cushing syndrome. Among patients treated with high-dose steroids the incidence is difficult to measure. Exposure to equivalents of 30 mg of prednisone per day causes proximal muscle weakness and atrophy especially of the lower extremities [<xref rid="cit0009" ref-type="bibr">9</xref>].</p><p>Myopathy usually begins after weeks of therapy but can appear even after a single dose. As well as the chronic condition related to endogenic or exogenic glucocorticoid excess, there is also a risk of developing acute myopathy with rhabdomyolysis, which may occur after 5&#x02013;7 days after the onset of treatment with high-dose glucocorticosteroids [<xref rid="cit0010" ref-type="bibr">10</xref>].</p><p>The most frequent symptom is reduction of muscle strength of the pelvic girdle and knee joint muscles, which results in declared difficulty climbing stairs and arising from low chairs. Women are more often affected than men, fluorinated synthetic glucocorticosteroids (dexamethasone, betamethasone, triamcinolone) are more likely to cause the condition than non-fluorinated agents, and an alternate-day regimen reduces the risk of myopathy [<xref rid="cit0011" ref-type="bibr">11</xref>]. Upper extremities are less affected. Distal, bulbar, neck muscles, and muscle stretch reflexes are normal, and myalgia is not present. CK levels are normal, EMG shows only subtle myopathic changes with no fibrillation potentials, and muscle biopsy reveals atrophy of mainly fast twitch type 2 fibres [<xref rid="cit0012" ref-type="bibr">12</xref>].</p><p>Muscle symptoms may be the predominant or the only clinical manifestation of hypothyroidism, and they can precede biochemical hypothyroidism or occur simultaneously [<xref rid="cit0013" ref-type="bibr">13</xref>]. Elevation of CK and/or LDH levels in serum that accompanies hypercholesterolaemia, hyponatraemia, hyperprolactinaemia, or anaemia should implicate the test for TSH. In this condition, well-known symptoms of thyroid hormone deficiency: somnolence, cold intolerance, depressed mood, are accompanied by exercise intolerance, myalgia, cramps, stiffness, myoedema, especially of the calves, and carpal and tarsal tunnel syndromes. EMG shows primary myopathic changes, but only in half of the patients [<xref rid="cit0014" ref-type="bibr">14</xref>].</p><p>Muscle biopsy shows fibre size variation, type I fibre predominance, type 2 atrophy, internal nuclei, sporadic necrosis and regeneration [<xref rid="cit0015" ref-type="bibr">15</xref>], and disrupted mitochondria and glycogen accumulation [<xref rid="cit0016" ref-type="bibr">16</xref>], both beneath sarcolemmal membrane and between myofibrils; in a way, hypothyroidism induces metabolic myopathy. Accumulation of glycogen deposits disappear and CK values normalise within weeks of L-T4 therapy.</p><p>Excess of thyroid gland hormones can also be a cause of thyrotoxic myopathy. Muscle weakness is a complaint of up to 67% of patients with hyperthyroidism. This condition presents with proximal muscle weakness and heat intolerance. The shoulder girdle is most frequently affected, and in rare instances it presents with winging of the scapula. It more commonly affects elderly patients, more frequently men than women. Myalgia is not observed. Some patients develop reversible facial, bulbar, oesophagopharyngeal, and diaphragmatic muscle weakness producing various symptoms such as dysphagia and dyspnoea. Deep tendon reflexes may be normal or hyperactive, although the relaxation phase is often shortened. The severity is not associated with biochemical parameters, but with the duration of hyperthyroidism [<xref rid="cit0017" ref-type="bibr">17</xref>].</p><p>Creatine kinase levels are normal, EMG may show subtle non-specific changes, muscle biopsy reveals type 1 and 2 muscle atrophy, fatty infiltration, muscle fibre necrosis, and lymphocytic infiltration [<xref rid="cit0018" ref-type="bibr">18</xref>]. Usually the condition resolves 3&#x02013;6 months after restoring euthyreosis; some patients report subjective improvement after treatment with a &#x003b2;-adrenergic blocker.</p><p>Diabetic myonecrosis, or diabetic muscle infarction, occurs in patients with long-lasting and poorly-controlled diabetes mellitus. It affects lower limbs in a focal manner, which makes it similar to focal myositis and may resemble relapse of myositis in patients chronically treated with glucocorticosteroids.</p><p>Only about 200 cases [<xref rid="cit0019" ref-type="bibr">19</xref>] were reported since it was first described in 1965. It presents as unilateral sudden pain and swelling of a muscle, usually of the thigh. CK levels are normal. Deep vein thrombosis should be excluded first by ultrasound. The key to the correct diagnosis, however, is MRI, which shows hyperintense signal on T2-weighted images and an isointense to hypointense signal on T1-weighted images from the affected muscle as well as perifascial, perimuscular, and subcutaneous oedema. Muscle biopsy is contraindicated because it prolongs time to recovery [<xref rid="cit0020" ref-type="bibr">20</xref>]. The condition is well managed by bed-rest, non-steroidal anti-inflammatory drugs, and proper glycaemic control.</p></sec><sec id="sec4"><title>Late-onset muscle dystrophies</title><p>Facioscapulohumeral muscular dystrophy (FSHD) type 1 and type 2 are congenital myopathies inherited in autosomal dominant pattern. The disease is of variable penetrance and has an incidence of 1 : 8,000 to 1 : 22,000, which makes it the third most common dystrophy, after Duchenne muscular dystrophy and myotonic dystrophy. A classical clinical presentation is descending muscle weakness, as suggested by the name itself: in the first decade of life it is in the form of mild weakness of the orbital, mouth muscles (children sleeping with their eyes slightly open, difficulty whistling); the shoulder girdle is affected in the second decade of life (asymmetrical winged scapula, difficulty lifting objects above the head, straight clavicles, vertical or reversed anterior axillary fold, caved-in chest); lower abdominal (lumbar hyperlordosis), and pelvic girdle weakness may follow. However, up to 18% of patients may have facial muscles spared and late-onset cases (&#x0003e; 50 years old) have also been reported [<xref rid="cit0021" ref-type="bibr">21</xref>], which suggests acquired conditions such as IIM. CK is only mildly elevated &#x02013; EMG shows discrete myopathic changes, and even MRI-guided muscle biopsy reveals the endomysial inflammatory cells surrounding intact fibres.</p><p>There is also a rapidly growing list of limb-girdle muscular dystrophies (LGMD), to-date having 21 subtypes, of which the most common are calpainopathy (LGMD2A), sarcoglycanopathy (LGMD2C-F), and dysferlinopathy (LGMD2B).</p><p>In the case of calpainopathy, lower limb weakness onset age ranges from 1 to 67 years, mean age 13 years, gradually affecting upper limbs within two years and leading to loss of ambulation within 20 years of its course. Winged scapula may be present, but no calf enlargement or cardiac complications are observed. Muscle biopsy shows severe endomysial fibrosis among other dystrophic changes (variation in fibre calibre, with focal necrosis and phagocytosis, and fibre splitting). Western blot studies may present abnormal calpain levels, but confirmatory genetic studies are essential for diagnosis.</p><p>The first symptoms of sarcoglycanopathy usually occur at around six years old, with onset age ranging from 1 to 30 years. Typical symptoms are true calf muscle hypertrophy (in contrast to pseudo-hypertrophy in Duchenne dystrophy), proximal weakness, frequent falls, Gowers manoeuvre, and rapid evolution to gait loss. Cardiac complications also occur, e.g. dilated cardiomyopathy. Muscle biopsy shows dystrophic changes, typically with no lobulated fibres.</p><p>Dysferlinopathy symptoms usually reveal themselves around the age of 19 years, but later onsets (to 58 years old) and subacute presentation have also been reported [<xref rid="cit0022" ref-type="bibr">22</xref>, <xref rid="cit0023" ref-type="bibr">23</xref>], making it difficult to differentiate from inflammatory myopathy. Lower limb weakness is followed by upper limbs in various period of time (1&#x02013;16 years); calf volume can be increased. CK levels are significantly elevated, resembling IIM, and MRI presents with hyperintensive patches very similar to polymyositis on STIR-weighted sequences [<xref rid="cit0024" ref-type="bibr">24</xref>]. Necrosis, phagocytosis, and regeneration can accompany typical dystrophic findings in muscle biopsy, which may point to IMNM.</p><p>It is crucial to ask the patient about previous family history of muscle diseases. It often requires asking the patients&#x02019; parents to come for an examination. Genetic testing is necessary for diagnosis in patients with no family history of dystrophies. Although currently there is no available effective treatment for these conditions, symptoms can be alleviated by e.g. proper kinetic therapy, pain assessment, or surgical scapular fixation [<xref rid="cit0025" ref-type="bibr">25</xref>]. There is still some hope in genetic therapies that are being developed. Some authors suggest that patients may benefit from immunosuppressive treatment, glucocorticoids, or TNF-inhibitors, if started early [<xref rid="cit0026" ref-type="bibr">26</xref>].</p></sec><sec id="sec5"><title>Lambert-Eaton myasthenic syndrome</title><p>Of many forms of autoimmune neuromuscular junction diseases, perhaps the one worth mentioning is Lambert-Eaton myasthenic syndrome, which can be misdiagnosed with IIM for its lack of typical muscle fatigability, the presence of sicca symptoms, and frequently underlying neoplastic disease, because the syndrome is often associated with small-cell lung cancer. The disease results from the presence of antibodies directed against the voltage-gated calcium channels, preventing acetylcholine release from the presynaptic nerve terminals. It presents with slowly progressive symmetrical proximal muscle weakness with normal or decreased levels of muscle enzymes, but subacute onsets were also noted.</p><p>Proximal muscle strength, deep tendon reflexes are depressed or even absent, but reappear after a 10&#x02013;15 seconds of isometric contraction (post-activation facilitation), contrary to the typical muscle fatigability of myasthenia gravis. Cranial nerve involvement is not common, but ptosis or diplopia should strongly suggest the diagnosis. Autonomic symptoms can accompany musculoskeletal complains: dry mouth, erectile dysfunction, constipation, vision disturbances [<xref rid="cit0027" ref-type="bibr">27</xref>].</p><p>Distinctive electromyographic findings include reduced baseline amplitude of muscle action potential and significant increase after high-frequency stimulation or exercise; serological tests may serve as confirmation of the diagnosis. Chemotherapy and/or immunosuppression is the treatment of choice.</p></sec><sec id="sec6"><title>Late-onset metabolic myopathies</title><p>Glycogenosis type II (also known as Pompe disease) is an autosomal-recessive disease, known to occur in about 1 : 50,000 people, caused by the deficiency of acid &#x003b1;-glucosidase (GAA). The severity of the disease varies from fatal neonatal (with very low enzyme level) to slowly progressive adult form. Symptoms of late-onset disease are weakness of proximal and axial muscles, often affecting the diaphragm and leading to respiratory insufficiency, and sometimes also affecting the heart muscle, causing cardiac hypertrophy and conduction abnormalities [<xref rid="cit0028" ref-type="bibr">28</xref>].</p><p>Considering symmetrical involvement of proximal muscles and insidious onset, the disease is often thought to be of autoimmune origin and is treated with corticosteroids. The histopathological hallmark of the disease is muscle fibre vacuolisation, which shows PAS (Periodic Acid-Schiff)-positive staining. Diagnosis is possible with blood spot enzymology and confirmatory genetic testing. Pompe disease is the only glycogenosis that has the possibility of pharmacological treatment with a recombinant GAA enzyme administered intravenously twice a week for at least one year [<xref rid="cit0029" ref-type="bibr">29</xref>]; however, treatment has to be initiated soon after the weakness or cardiological symptoms appear. The treatment does not reverse the disability of affected respiratory muscles.</p><p>Glycogenosis type V (McArdle disease) results from deficiency of myophosphorylase and is characterised by fatigue and exercise-induced myalgia and episodic rhabdomyolysis, which can lead to myoglobinuria and renal failure. Proximal muscles, especially of the shoulder girdle, may also be affected later in life. Subsarcolemmal PAS-positive blebs can be found in the muscle biopsy, but the diagnosis is confirmed by histoenzymatic stain for the phosphorylase and a genetic test. Patients alleviate the symptoms by using the &#x0201c;second-wind&#x0201d; phenomenon: mild aerobic exercise 10 minutes before the exertion raises the availability of blood-borne glucose in muscles and reduces myalgia [<xref rid="cit0030" ref-type="bibr">30</xref>]. Current treatment recommendations comprise kinetic therapy, a carbohydrate-rich diet, and vitamin B6 supplementation.</p><p>Neutral lipid storage disease with myopathy (NLSD-M) presents as slowly progressive proximal muscle weakness affecting the upper limbs, cardiomyopathy, and elevated CK level resembling IIM, accompanied by hepatic steatosis, hypertriglyceridaemia, diabetes mellitus, and sensorineural hearing loss [<xref rid="cit0031" ref-type="bibr">31</xref>].</p><p>Muscle biopsy shows neutral lipid storage with the appearance of vacuolated fibres and increased Oil-Red-O droplets, especially in the atrophic fibres. Peripheral blood microscopic smear test shows Jordan&#x02019;s anomaly &#x02013; lipid droplets in the cytoplasm of leukocytes. There is currently no effective treatment.</p><p>Multiple acyl-CoA dehydrogenase deficiency (MADD) is a mitochondrial myopathy that is characterised by proximal muscle weakness, high CK levels, vomiting, and hypoglycaemia [<xref rid="cit0032" ref-type="bibr">32</xref>]. Additional laboratory tests show low free carnitine but elevated acyl-carnitines; muscle biopsy presents lipid storage myopathy. The condition responds well to riboflavin and carnitine supplementation.</p><p>Carnitine palmitoyl transferase II (CPT-II) deficiency is another mitochondrial myopathy, which produces cramps, myalgia, and exercise intolerance. Episodes of rhabdomyolysis, high CK levels, and myoglobinuria occur, triggered by prolonged exercise, cold, fever, fasting, or anaesthetic drugs. It can be managed by intravenous glucose administration but can require dialysis in some severe cases. Muscle examination reveals fibres with small vacuoles and lipid droplet accumulation. Adopting appropriate lifestyle recommendations and diet [<xref rid="cit0033" ref-type="bibr">33</xref>] prevents the episodes of rhabdomyolysis.</p></sec><sec id="sec7"><title>Infections</title><p>Myositis can also be caused by infectious pathogens: viral, bacterial, fungal, and parasitic. Usually it is mild or of limited distribution; however, the viral infections are the ones that are best known to produce generalised disease [<xref rid="cit0034" ref-type="bibr">34</xref>].</p><p>Myalgia is a common complaint of patients having a common influenza infection, it can follow or precede other symptoms, such as cough, headache, rhinorrhoea, viral pneumonia, myocarditis, and meningoencephalitis. Myositis can occur approximately three days after the onset of symptoms of infection (0&#x02013;18 days), it usually starts as calf pain and difficulty with difficulty in ambulation, and it occurs more often in children and in type B infection [<xref rid="cit0035" ref-type="bibr">35</xref>]; however, it is type A that is more often associated with rhabdomyolysis.</p><p>Muscle enzyme levels are elevated, myopathic changes are noted in the EMG, and muscle biopsy, when performed, can reveal degeneration and necrosis with small inflammatory cells infiltration [<xref rid="cit0036" ref-type="bibr">36</xref>], as in IMNM. The course of the disease is self-limiting, results within three days (1&#x02013;30 days). There is no proven effective treatment except for symptomatic management.</p><p>Similar cases have been reported to be associated with coxsackieviruses type A and B [<xref rid="cit0037" ref-type="bibr">37</xref>], enteric cytopathogenic human orphan (ECHO) viruses [<xref rid="cit0038" ref-type="bibr">38</xref>], adenoviruses [<xref rid="cit0039" ref-type="bibr">39</xref>], and respiratory syncytial virus [<xref rid="cit0040" ref-type="bibr">40</xref>].</p><p>Human immunodeficiency virus (HIV) can cause nemaline myopathy and can be a triggering factor of amyotrophic lateral sclerosis, bibrachial amyotrophic diplegia, and inflammatory muscle diseases like IMNM at any time in its course [<xref rid="cit0041" ref-type="bibr">41</xref>]. Sporadic late-onset nemaline myopathy associated with HIV infection is characterised by subacute proximal muscle weakness of the limbs; often neck, pharyngeal and respiratory muscles are affected as well. There have been reports on progressive external ophthalmoplegia [<xref rid="cit0042" ref-type="bibr">42</xref>].</p><p>Tendon reflexes are depressed and fasciculations may appear. CK levels are normal, but laboratory tests show hypergammaglobulinaemia of monoclonal or polyclonal character, which normalises during highly active antiretroviral therapy (HAART). Muscle biopsy shows characteristic red rods of actin with Gomori stain. It is justified to screen myositis patients for HIV infection because these myopathies are usually of good prognosis, and patients respond well to HAART and immunosuppressive treatment, like glucocorticoids and intravenous immunoglobulins [<xref rid="cit0041" ref-type="bibr">41</xref>]. As it has been described above, however, antiretroviral therapy itself can cause musculoskeletal adverse effects.</p><p>There have also been reports of myositis caused by human T-cell lymphotropic virus type 1 (HTLV-1) [<xref rid="cit0043" ref-type="bibr">43</xref>], hepatitis B and C [<xref rid="cit0044" ref-type="bibr">44</xref>], cytomegalovirus [<xref rid="cit0045" ref-type="bibr">45</xref>], Epstein-Barr virus [<xref rid="cit0046" ref-type="bibr">46</xref>], herpes simplex virus [<xref rid="cit0047" ref-type="bibr">47</xref>], varicella-zoster virus [<xref rid="cit0048" ref-type="bibr">48</xref>], and dengue [<xref rid="cit0049" ref-type="bibr">49</xref>].</p><p>Bacterial pyomyositis presents as local pain and oedema of &#x02018;woody&#x02019; texture, which turns into severe pain and fever and finally sepsis within 2&#x02013;3 weeks. Any skeletal muscle can be affected, although the most vulnerable are the lower extremities, because the condition is thought to be associated with local trauma. Diagnosis can be difficult because many patients are from the immunosuppressed or HIV-positive group; however, the inflammatory markers that are more elevated than the muscle enzymes. 60&#x02013;90% of cases are caused by <italic>Staphylococcus aureus</italic>, secondly <italic>Streptococcus pneumoniae</italic>, but type B, C, and G <italic>streptococci</italic>, and less commonly <italic>Clostridium</italic> spp.<italic>, Mycobacterium</italic> spp.<italic>,</italic> are also known to produce the condition. In its early stages, it can be confirmed by ultrasound, CT, or MRI and treated with empirical antibiotics covering firstly S. aureus (remembering of risk of MRSA), but puncture, drainage, or surgical open procedure often become necessary in later stages [<xref rid="cit0050" ref-type="bibr">50</xref>].</p><p>Despite the fact that mild arthralgia and myalgia often occur in the course of Lyme borreliosis (and post-borreliosis), Lyme myositis is usually localised and appears simultaneously with other symptoms like monoarthritis and typical skin lesions. CK is normal or only mildly elevated, but generalised myositis and rhabdomyolysis cases have also been reported [<xref rid="cit0051" ref-type="bibr">51</xref>]. Histopathology shows interstitial muscle macrophages and T helper cell infiltrates near small blood vessels, often associated with fibre degeneration. Silver stains for spirochetes sometimes visualise the microorganisms in affected tissue. Penicillin, cephalosporins, and tetracyclines are effective treatment options.</p><p>Some parasitic myopathies tend to be more diffuse in nature. Katayama syndrome, caused by <italic>Schistosoma</italic> spp., presents as generalised myalgia, reduction of muscle mass, and weakness (especially of the pelvic diaphragm, causing rectal prolapse) accompanied by fever, chills, cough, headache, abdominal tenderness, and urticaria. Kato-Katz smear of stool is helpful for diagnosis, and treatment comprises of praziquantel and glucocorticosteroids. Muscle involvement occurs in 75% of patients with neurocysticercosis, caused by <italic>Taenia</italic> spp. Diffuse disease presents as calcifications in the muscle bundles in the thighs or arms.</p><p>Fungal myositis should be suspected when fever, rash, and myalgia [<xref rid="cit0052" ref-type="bibr">52</xref>] occur in immunosuppressed patients. The most common causative pathogen is <italic>Candida tropicalis</italic> or other <italic>Candida</italic> spp. Muscle MRI shows numerous microabscesses, and the disease is confirmed by the presence of yeast and pseudohyphae in muscle biopsy. Mortality rates are high [<xref rid="cit0053" ref-type="bibr">53</xref>].</p></sec><sec sec-type="conclusions" id="sec8"><title>Conclusions</title><p>Retrospective studies show that elevated CK levels are found in as many as 8% of patients seeking healthcare professional aid, of which rheumatological conditions account for only 0.8% of cases [<xref rid="cit0054" ref-type="bibr">54</xref>]. What is more, 45% of patients referred to rheumatologists are finally not confirmed to have IIM. The true reason for the illness is found to be caused by drugs in 8%, infection in 6%, and trauma in 5%; of note, 6% of patients have only idiopathic CK-aemia [<xref rid="cit0055" ref-type="bibr">55</xref>]. In <xref ref-type="fig" rid="f0001">Figure 1</xref> the all-causes myopathy is shown.</p><fig id="f0001" position="float"><label>Fig. 1</label><caption><p>Diagram of causes of myopathy.</p></caption><graphic xlink:href="RU-56-79502-g001"/></fig><p>Looking back at the IIM Peter and Bohan diagnostic criteria, we can see that neither of the five is distinctive for autoimmune disease. Several symptoms, however, serve in favour: subacute onset, skin lesions (e.g. Gottron&#x02019;s papules, heliotrope rashes, photosensitivity), symmetrical, proximal muscle groups involvement, Raynaud&#x02019;s phenomenon, arthritis, and interstitial lung disease. Certainly, pathological muscle examination may play a crucial role in diagnosis, hence the necessity for guided biopsy techniques. Several symptoms should raise caution or even lead away from diagnosis of IIM: very slow and gradual progression or variable dynamics of symptoms, very early onset, a similar family history, weakness or myalgia related to exercise and fasting, fatigability, fasciculations, asymmetrical distribution, facial involvement, accompanying cataract or diabetes, severe myalgia, or remarkedly elevated inflammatory markers. One condition, however, never entirely excludes another. Any previously existing muscular disease is a risk factor for developing inflammatory myopathy, and any myopathy can appear independently during the course of the disease, impeding the assessment of disease activity.</p></sec></body><back><fn-group><fn><p>The rights revenue was paid by Stowarzyszenie Zbiorowego Zarz&#x00105;dzania Prawami Autorskimi Tw&#x000f3;rc&#x000f3;w Dzie&#x00142; Naukowych i Technicznych KOPIPOL of Kielce from fees collected pursuant to Article 20 and Article 20<sup>1</sup> of the Copyright and Neighbouring Rights Act.</p><p>Wynagrodzenie autorskie sfinansowane zosta&#x00142;o przez Stowarzyszenie Zbiorowego Zarz&#x00105;dzania Prawami Autorskimi Tw&#x000f3;rc&#x000f3;w Dzie&#x00142; Naukowych i Technicznych KOPIPOL z siedzib&#x00105; w Kielcach z op&#x00142;at uzyskanych na podstawie art. 20 oraz art. 20&#x000b9; ustawy o prawie autorskim i prawach pokrewnych.</p></fn><fn fn-type="COI-statement"><p>The authors declare no conflict of interest.</p></fn></fn-group><ref-list><title>References</title><ref id="cit0001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasnoor</surname><given-names>M</given-names></name><name><surname>Barohn</surname><given-names>RJ</given-names></name><name><surname>Dimachkie</surname><given-names>MM</given-names></name></person-group><article-title>Toxic myopathies</article-title><source>Neurol Clin</source><year>2014</year><volume>32</volume><fpage>647</fpage><lpage>670</lpage><pub-id pub-id-type="pmid">25037083</pub-id></element-citation></ref><ref id="cit0002"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>M</given-names></name><name><surname>Matthews</surname><given-names>ML</given-names></name><name><surname>Jarvis</surname><given-names>C</given-names></name><etal/></person-group><article-title>Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy</article-title><source>Clin Ther</source><year>2007</year><volume>29</volume><fpage>253</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">17472818</pub-id></element-citation></ref><ref id="cit0003"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Needham</surname><given-names>M</given-names></name><name><surname>Fabian</surname><given-names>V</given-names></name><name><surname>Knezevic</surname><given-names>W</given-names></name><etal/></person-group><article-title>Progressive myopathy with up-regulation of MHCI associated with statin therapy</article-title><source>Neuromuscul Disord</source><year>2007</year><volume>17</volume><fpage>194</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">17241784</pub-id></element-citation></ref><ref id="cit0004"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mammen</surname><given-names>AL</given-names></name><name><surname>Chung</surname><given-names>T</given-names></name><name><surname>Christopher-Stine</surname><given-names>L</given-names></name><etal/></person-group><article-title>Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy</article-title><source>Arthritis Rheum</source><year>2011</year><volume>63</volume><fpage>713</fpage><lpage>721</lpage><pub-id pub-id-type="pmid">21360500</pub-id></element-citation></ref><ref id="cit0005"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohassel</surname><given-names>P</given-names></name><name><surname>Mammen</surname><given-names>AL</given-names></name></person-group><article-title>The spectrum of statin myopathy</article-title><source>Curr Opin Rheumatol</source><year>2013</year><volume>25</volume><fpage>747</fpage><lpage>752</lpage><pub-id pub-id-type="pmid">24061077</pub-id></element-citation></ref><ref id="cit0006"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grable-Esposito</surname><given-names>P</given-names></name><name><surname>Katzberg</surname><given-names>HD</given-names></name><name><surname>Greenberg</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Immune-mediated necrotizing myopathy associated with statins</article-title><source>Muscle Nerve</source><year>2010</year><volume>41</volume><fpage>185</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">19813188</pub-id></element-citation></ref><ref id="cit0007"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mammen</surname><given-names>AL</given-names></name></person-group><article-title>Necrotizing myopathies: beyond statins</article-title><source>Curr Opin Rheumatol</source><year>2014</year><volume>26</volume><fpage>679</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">25203117</pub-id></element-citation></ref><ref id="cit0008"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preedy</surname><given-names>VR</given-names></name><name><surname>Ohlendieck</surname><given-names>K</given-names></name><name><surname>Adachi</surname><given-names>J</given-names></name><etal/></person-group><article-title>The importance of alcohol-induced muscle disease</article-title><source>J Muscle Res Cell Motil</source><year>2003</year><volume>24</volume><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">12953836</pub-id></element-citation></ref><ref id="cit0009"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khaleeli</surname><given-names>AA</given-names></name><name><surname>Edwards</surname><given-names>RH</given-names></name><name><surname>Gohil</surname><given-names>K</given-names></name><etal/></person-group><article-title>Corticosteroid myopathy: a clinical and pathological study</article-title><source>Clin Endocrinol</source><year>1983</year><volume>18</volume><fpage>155</fpage><lpage>166</lpage></element-citation></ref><ref id="cit0010"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanson</surname><given-names>P</given-names></name><name><surname>Dive</surname><given-names>A</given-names></name><name><surname>Brucher</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Acute corticosteroid myopathy in intensive care patients</article-title><source>Muscle Nerve</source><year>1997</year><volume>20</volume><fpage>1371</fpage><lpage>1380</lpage><pub-id pub-id-type="pmid">9342153</pub-id></element-citation></ref><ref id="cit0011"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faludi</surname><given-names>G</given-names></name><name><surname>Gotlieb</surname><given-names>J</given-names></name><name><surname>Meyers</surname><given-names>J</given-names></name></person-group><article-title>Factors influencing the development of steroid-induced myopathies</article-title><source>Ann N Y Acad Sci</source><year>1966</year><volume>138</volume><fpage>62</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">5230216</pub-id></element-citation></ref><ref id="cit0012"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacomis</surname><given-names>D</given-names></name><name><surname>Giuliani</surname><given-names>MJ</given-names></name><name><surname>Van Cott</surname><given-names>A</given-names></name><name><surname>Kramer</surname><given-names>DJ</given-names></name></person-group><article-title>Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects</article-title><source>Ann Neurol</source><year>1996</year><volume>40</volume><fpage>645</fpage><lpage>654</lpage><pub-id pub-id-type="pmid">8871585</pub-id></element-citation></ref><ref id="cit0013"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood-Allum</surname><given-names>CA</given-names></name><name><surname>Shaw</surname><given-names>PJ</given-names></name></person-group><article-title>Thyroid disease and the nervous system</article-title><source>Handb Clin Neurol</source><year>2014</year><volume>120</volume><fpage>703</fpage><lpage>735</lpage><pub-id pub-id-type="pmid">24365348</pub-id></element-citation></ref><ref id="cit0014"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duyff</surname><given-names>RF</given-names></name><name><surname>Van den Bosch</surname><given-names>JV</given-names></name><name><surname>Laman</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2000</year><volume>68</volume><fpage>750</fpage><lpage>755</lpage><pub-id pub-id-type="pmid">10811699</pub-id></element-citation></ref><ref id="cit0015"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodolico</surname><given-names>C</given-names></name><name><surname>Toscano</surname><given-names>A</given-names></name><name><surname>Benvenga</surname><given-names>S</given-names></name><name><surname>Vita</surname><given-names>G</given-names></name></person-group><article-title>Skeletal muscle disturbances may precede clinical and laboratory evidence of autoimmune hypothyroidism</article-title><source>J Neurol</source><year>1998</year><volume>245</volume><fpage>555</fpage><lpage>556</lpage><pub-id pub-id-type="pmid">9747921</pub-id></element-citation></ref><ref id="cit0016"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDaniel</surname><given-names>HG</given-names></name><name><surname>Pittman</surname><given-names>CS</given-names></name><name><surname>Oh</surname><given-names>SJ</given-names></name><name><surname>Di Mauro</surname><given-names>S</given-names></name></person-group><article-title>Carbohydrate metabolism in hypothyroid myopathy</article-title><source>Metabolism</source><year>1977</year><volume>26</volume><fpage>867</fpage><lpage>873</lpage><pub-id pub-id-type="pmid">875732</pub-id></element-citation></ref><ref id="cit0017"><label>17</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Amato</surname><given-names>AA</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Brown</surname><given-names>WF</given-names></name><name><surname>Bolton</surname><given-names>CF</given-names></name><name><surname>Aminoff</surname><given-names>MJ</given-names></name></person-group><article-title>Endocrine myopathies and toxic myopathies</article-title><source>Neuromuscular Function and Disease: Basic, Clinical, and Electrodiagnostic Aspects</source><year>2002</year><volume>2</volume><publisher-loc>Philadelphia</publisher-loc><publisher-name>W.B. Saunders</publisher-name><fpage>1399</fpage><lpage>1402</lpage></element-citation></ref><ref id="cit0018"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celsing</surname><given-names>F</given-names></name><name><surname>Blomstrand</surname><given-names>E</given-names></name><name><surname>Melichna</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effect of hyperthyroidism on fibre area, glycogen content, and enzyme activity in human skeletal muscle</article-title><source>Clin Physiol</source><year>1986</year><volume>6</volume><fpage>171</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">2937605</pub-id></element-citation></ref><ref id="cit0019"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iyer</surname><given-names>SN</given-names></name><name><surname>Drake</surname><given-names>AJ</given-names><suffix>III</suffix></name><name><surname>West</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Diabetic muscle infarction: a rare complication of long-standing and poorly controlled diabetes mellitus</article-title><source>Case Rep Med</source><year>2011</year><volume>2011</volume><fpage>407921</fpage><pub-id pub-id-type="pmid">22007231</pub-id></element-citation></ref><ref id="cit0020"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barohn</surname><given-names>RJ</given-names></name><name><surname>Kissel</surname><given-names>JT</given-names></name></person-group><article-title>Case of the month: painful thigh mass in a young woman: diabetic muscle infarction</article-title><source>Muscle Nerve</source><year>1992</year><volume>15</volume><fpage>850</fpage><lpage>855</lpage><pub-id pub-id-type="pmid">1501628</pub-id></element-citation></ref><ref id="cit0021"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pastorello</surname><given-names>E</given-names></name><name><surname>Cao</surname><given-names>M</given-names></name><name><surname>Trevisan</surname><given-names>CP</given-names></name></person-group><article-title>Atypical onset in a series of122 cases with facioscapulohumeral muscular dystrophy</article-title><source>Clin Neurol Neurosurg</source><year>2012</year><volume>114</volume><fpage>230</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">22079131</pub-id></element-citation></ref><ref id="cit0022"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paradas</surname><given-names>C</given-names></name><name><surname>Gonz&#x000e1;lez-Quereda</surname><given-names>L</given-names></name><name><surname>De Luna</surname><given-names>N</given-names></name><etal/></person-group><article-title>A new phenotype of dysferlinopathy with congenital onset</article-title><source>Neuromuscul Disord</source><year>2009</year><volume>19</volume><fpage>21</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">19084402</pub-id></element-citation></ref><ref id="cit0023"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Aoki</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>N</given-names></name><etal/></person-group><article-title>Clinical features and a mutation with late onset of limb girdle muscular dystrophy 2B</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2013</year><volume>84</volume><fpage>433</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">23243261</pub-id></element-citation></ref><ref id="cit0024"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Degardin</surname><given-names>A</given-names></name><name><surname>Morillon</surname><given-names>D</given-names></name><name><surname>Lacour</surname><given-names>A</given-names></name><etal/></person-group><article-title>Morphologic imaging in muscular dystrophies and inflammatory myopathies</article-title><source>Skeletal Radiol</source><year>2010</year><volume>39</volume><fpage>1219</fpage><lpage>1227</lpage><pub-id pub-id-type="pmid">20449587</pub-id></element-citation></ref><ref id="cit0025"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cotta</surname><given-names>A</given-names></name><name><surname>Carvalho</surname><given-names>E</given-names></name><name><surname>da-Cunha-J&#x000fa;nior</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Common recessive limb girdle muscular dystrophies differential diagnosis: why and how?</article-title><source>Arq Neuro-Psiquiatr</source><year>2014</year><volume>72</volume><fpage>721</fpage><lpage>734</lpage></element-citation></ref><ref id="cit0026"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tidball</surname><given-names>JG</given-names></name><name><surname>Wehling-Henricks</surname><given-names>M</given-names></name></person-group><article-title>Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis</article-title><source>Curr Opin Rheumatol</source><year>2005</year><volume>17</volume><fpage>707</fpage><lpage>713</lpage><pub-id pub-id-type="pmid">16224247</pub-id></element-citation></ref><ref id="cit0027"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Suilleabhain</surname><given-names>P</given-names></name><name><surname>Low</surname><given-names>PA</given-names></name><name><surname>Lennon</surname><given-names>VA</given-names></name></person-group><article-title>Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates</article-title><source>Neurology</source><year>1998</year><volume>50</volume><fpage>88</fpage><pub-id pub-id-type="pmid">9443463</pub-id></element-citation></ref><ref id="cit0028"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x000fc;ller</surname><given-names>A</given-names></name><name><surname>Wenninger</surname><given-names>S</given-names></name><name><surname>Strigl-Pill</surname><given-names>N</given-names></name><name><surname>Schoser</surname><given-names>B</given-names></name></person-group><article-title>Toward deconstructing the phenotype of late-onset Pompe disease</article-title><source>Am J Med Genet C: Semin Med Genet</source><year>2012</year><volume>160</volume><fpage>80</fpage><lpage>88</lpage></element-citation></ref><ref id="cit0029"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cupler</surname><given-names>EJ</given-names></name><name><surname>Berger</surname><given-names>KI</given-names></name><name><surname>Leshner</surname><given-names>RT</given-names></name><etal/></person-group><article-title>AANEM Consensus Committee on Late-onset Pompe Disease. Consensus treatment recommendations for late-onset Pompe disease</article-title><source>Muscle Nerve</source><year>2012</year><volume>45</volume><fpage>319</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">22173792</pub-id></element-citation></ref><ref id="cit0030"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucia</surname><given-names>A</given-names></name><name><surname>Quinlivan</surname><given-names>R</given-names></name><name><surname>Wakelin</surname><given-names>A</given-names></name><etal/></person-group><article-title>The &#x02018;McArdle paradox&#x02019;: exercise is a good advice for the exercise intolerant</article-title><source>Br J Sports Med</source><year>2013</year><volume>47</volume><fpage>728</fpage><lpage>729</lpage><pub-id pub-id-type="pmid">22753862</pub-id></element-citation></ref><ref id="cit0031"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>J</given-names></name><name><surname>Lefevre</surname><given-names>C</given-names></name><name><surname>Morava</surname><given-names>E</given-names></name><etal/></person-group><article-title>The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>28</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">17187067</pub-id></element-citation></ref><ref id="cit0032"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>WC</given-names></name><name><surname>Nishino</surname><given-names>I</given-names></name></person-group><article-title>Lipid storage myopathy</article-title><source>Curr Neurol Neurosci Rep</source><year>2012</year><volume>11</volume><fpage>97</fpage><lpage>103</lpage></element-citation></ref><ref id="cit0033"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000d8;rngreen</surname><given-names>MC</given-names></name><name><surname>Ejstrup</surname><given-names>R</given-names></name><name><surname>Vissing</surname><given-names>J</given-names></name></person-group><article-title>Effect of diet on exercise tolerance in carnitine palmitoyltransferase II deficiency</article-title><source>Neurology</source><year>2003</year><volume>61</volume><fpage>559</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">12939440</pub-id></element-citation></ref><ref id="cit0034"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crum-Cianflone</surname><given-names>NF</given-names></name></person-group><article-title>Bacterial, fungal, parasitic, and viral myositis</article-title><source>Clin Microbiol Rev</source><year>2008</year><volume>21</volume><fpage>473</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">18625683</pub-id></element-citation></ref><ref id="cit0035"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabbutt</surname><given-names>S</given-names></name><name><surname>Leonard</surname><given-names>M</given-names></name><name><surname>Godinez</surname><given-names>RI</given-names></name><etal/></person-group><article-title>Severe influenza B myocarditis and myositis</article-title><source>Pediatr Crit Care Med</source><year>2004</year><volume>5</volume><fpage>403</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">15215016</pub-id></element-citation></ref><ref id="cit0036"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>LE</given-names></name><name><surname>Kornfeld</surname><given-names>M</given-names></name></person-group><article-title>Experimental influenza B viral myositis</article-title><source>J Neurol Sci</source><year>2001</year><volume>187</volume><fpage>61</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">11440746</pub-id></element-citation></ref><ref id="cit0037"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fodili</surname><given-names>F</given-names></name><name><surname>van Bommel</surname><given-names>EF</given-names></name></person-group><article-title>Severe rhabdomyolysis and acute renal failure following recent Coxsackie B virus infection</article-title><source>Neth J Med</source><year>2003</year><volume>61</volume><fpage>177</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">12916546</pub-id></element-citation></ref><ref id="cit0038"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jehn</surname><given-names>UW</given-names></name><name><surname>Fink</surname><given-names>MK</given-names></name></person-group><article-title>Myositis, myoglobinemia, and myoglobinuria associated with enterovirus echo 9 infection</article-title><source>Arch Neurol</source><year>1980</year><volume>37</volume><fpage>457</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">7387495</pub-id></element-citation></ref><ref id="cit0039"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakata</surname><given-names>H</given-names></name><name><surname>Taketazu</surname><given-names>G</given-names></name><name><surname>Nagaya</surname><given-names>K</given-names></name><etal/></person-group><article-title>Outbreak of severe infection due to adenovirus type 7 in a paediatric ward in Japan</article-title><source>J Hosp Infect</source><year>1998</year><volume>39</volume><fpage>207</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">9699140</pub-id></element-citation></ref><ref id="cit0040"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naylor</surname><given-names>CD</given-names></name><name><surname>Jevnikar</surname><given-names>AM</given-names></name><name><surname>Witt</surname><given-names>NJ</given-names></name></person-group><article-title>Sporadic viral myositis in two adults</article-title><source>CMAJ</source><year>1987</year><volume>137</volume><fpage>819</fpage><lpage>821</lpage><pub-id pub-id-type="pmid">2832046</pub-id></element-citation></ref><ref id="cit0041"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>RW</given-names></name><name><surname>Williams</surname><given-names>FM</given-names></name><name><surname>Kazi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Human immunodeficiency virus-associated polymyositis: a longitudinal study of outcome</article-title><source>Arthritis Rheum</source><year>2003</year><volume>49</volume><fpage>172</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">12687507</pub-id></element-citation></ref><ref id="cit0042"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>RA</given-names></name><name><surname>Plant</surname><given-names>GT</given-names></name><name><surname>Landon</surname><given-names>DN</given-names></name><etal/></person-group><article-title>Nemaline myopathy: an unusual cause of ophthalmoparesis</article-title><source>J Neuroophthalmol</source><year>1997</year><volume>17</volume><fpage>39</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">9093960</pub-id></element-citation></ref><ref id="cit0043"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>OS</given-names></name><name><surname>Rodgers-Johnson</surname><given-names>P</given-names></name><name><surname>Mora</surname><given-names>C</given-names></name><name><surname>Char</surname><given-names>G</given-names></name></person-group><article-title>HTLV-1 and polymyositis in Jamaica</article-title><source>Lancet</source><year>1989</year><volume>2</volume><fpage>1184</fpage><lpage>1187</lpage><pub-id pub-id-type="pmid">2572904</pub-id></element-citation></ref><ref id="cit0044"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nojima</surname><given-names>T</given-names></name><name><surname>Hirakata</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><etal/></person-group><article-title>A case of polymyositis associated with hepatitis B infection</article-title><source>Clin Exp Rheumatol</source><year>2000</year><volume>18</volume><fpage>86</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">10728451</pub-id></element-citation></ref><ref id="cit0045"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>M</given-names></name><name><surname>Maeda</surname><given-names>A</given-names></name><name><surname>Wakiguchi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Polymyositis associated with primary cytomegalovirus infection</article-title><source>Scand J Infect Dis</source><year>2000</year><volume>32</volume><fpage>212</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">10826911</pub-id></element-citation></ref><ref id="cit0046"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchiyama</surname><given-names>T</given-names></name><name><surname>Arai</surname><given-names>K</given-names></name><name><surname>Yamamoto-Tabata</surname><given-names>T</given-names></name><etal/></person-group><article-title>Generalized myositis mimicking polymyositis associated with chronic active Epstein-Barr virus infection</article-title><source>J Neurol</source><year>2005</year><volume>252</volume><fpage>519</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">15742118</pub-id></element-citation></ref><ref id="cit0047"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlesinger</surname><given-names>JJ</given-names></name><name><surname>Gandara</surname><given-names>D</given-names></name><name><surname>Bensch</surname><given-names>KG</given-names></name></person-group><article-title>Myoglobinuria associated with herpes-group viral infections</article-title><source>Arch Intern Med</source><year>1978</year><volume>138</volume><fpage>422</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">629637</pub-id></element-citation></ref><ref id="cit0048"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badilla</surname><given-names>J</given-names></name><name><surname>Dolman</surname><given-names>PJ</given-names></name></person-group><article-title>Orbital myositis involving the oblique muscles associated with herpes zoster ophthalmicus</article-title><source>Ophthal Plast Reconstr Surg</source><year>2007</year><volume>23</volume><fpage>411</fpage><lpage>413</lpage></element-citation></ref><ref id="cit0049"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finsterer</surname><given-names>J</given-names></name><name><surname>Kongchan</surname><given-names>K</given-names></name></person-group><article-title>Severe, persisting, steroid-responsive Dengue myositis</article-title><source>J Clin Virol</source><year>2006</year><volume>35</volume><fpage>426</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">16414305</pub-id></element-citation></ref><ref id="cit0050"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crum-Cianflone</surname><given-names>NF</given-names></name></person-group><article-title>Bacterial, fungal, parasitic, and viral myositis</article-title><source>Clin Microbiol Rev</source><year>2008</year><volume>21</volume><fpage>473</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">18625683</pub-id></element-citation></ref><ref id="cit0051"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeandel</surname><given-names>C</given-names></name><name><surname>Perret</surname><given-names>C</given-names></name><name><surname>Blain</surname><given-names>H</given-names></name><etal/></person-group><article-title>Rhabdomyolysis with acute renal failure due to Borrelia burgdorferi [letter]</article-title><source>J Int Med</source><year>1994</year><volume>235</volume><fpage>191</fpage><lpage>192</lpage></element-citation></ref><ref id="cit0052"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jarowski</surname><given-names>CI</given-names></name><name><surname>Fialk</surname><given-names>MA</given-names></name><name><surname>Murray</surname><given-names>HW</given-names></name><etal/></person-group><article-title>Fever, rash, and muscle tenderness. Adistinctive clinical presentation of disseminated candidiasis</article-title><source>Arch Intern Med</source><year>1978</year><volume>138</volume><fpage>544</fpage><lpage>546</lpage><pub-id pub-id-type="pmid">637635</pub-id></element-citation></ref><ref id="cit0053"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diggs</surname><given-names>CH</given-names></name><name><surname>Eskenasy</surname><given-names>GM</given-names></name><name><surname>Sutherland</surname><given-names>JC</given-names></name><name><surname>Wiernik</surname><given-names>PH</given-names></name></person-group><article-title>Fungal infection of muscle in acute leukemia</article-title><source>Cancer</source><year>1976</year><volume>38</volume><fpage>1771</fpage><lpage>1772</lpage><pub-id pub-id-type="pmid">1068744</pub-id></element-citation></ref><ref id="cit0054"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grunau</surname><given-names>BE</given-names></name><name><surname>Pourvali</surname><given-names>R</given-names></name><name><surname>Wiens</surname><given-names>MO</given-names></name><etal/></person-group><article-title>Characteristics and thirty-day outcomes of emergency department patients with elevated creatine kinase</article-title><source>Acad Emerg Med</source><year>2014</year><volume>21</volume><fpage>631</fpage><lpage>636</lpage><pub-id pub-id-type="pmid">25039546</pub-id></element-citation></ref><ref id="cit0055"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leverenz</surname><given-names>D</given-names></name><name><surname>Zaha</surname><given-names>O</given-names></name><name><surname>Crofford</surname><given-names>LJ</given-names></name><name><surname>Chung</surname><given-names>CP</given-names></name></person-group><article-title>Causes of creatine kinase levels greater than 1000 IU/L in patients referred to rheumatology</article-title><source>Clin Rheumatol</source><year>2016</year><volume>35</volume><fpage>1541</fpage><lpage>1547</lpage><pub-id pub-id-type="pmid">27041384</pub-id></element-citation></ref></ref-list></back></article>